Clinical trials: Risperidone, completed
Schizophrenia Spectrum and Other Psychotic Disorders
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive…
- Trial name
- NCT03955549
- Testing
- Insight Enhancement Program (IEP), Metacognitive Training for Psychosis (MCT), Treatment As Usual (TAU)
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Agiad Psychiatry Hospital
Schizophrenia
Antipsychotic Response in Schizophrenia
Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental…
- Trial name
- NCT00018668
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Schizophrenia Schizoaffective
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
Lyndra is developing an oral, extended release (ER) formulation of risperidone (LYN-005) presented in a capsule dosage form with the intent of reducing the frequency of dosing orally-administered medications to once weekly or…
- Trial name
- NCT04567524
- Testing
- LYN-005
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Lyndra Inc.
Schizophrenia
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
- Trial name
- NCT02202213
- Testing
- Lu AF11167
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
- Trial name
- NCT00694707
- Testing
- Cariprazine, Risperidone
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 732 people
- Sponsor
- Forest Laboratories
Schizophrenia, Psychotic Disorders
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
The purpose of the study is to evaluate the maintained effectiveness of long-acting injectable risperidone (RISPERDAL® CONSTA™) compared with the previous treatment with oral olanzapine in non-acute subjects with schizophrenia or…
- Trial name
- NCT00216632
- Testing
- risperidone
- Volunteers
- 99 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Despite recent advances in the understanding and treatment of schizophrenia, this devastating disease still affects one percent of world's population.
- Trial name
- CBD-IS (NCT02051387)
- Testing
- Cannabidiol CR, Cannabidiol, Amisulpride
- Where
- 2 sites in Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Post-Traumatic Stress Disorder
Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma
This medical study is an assessment of clinical response in women with Posttraumatic Stress Disorder (PTSD) due to domestic violence or rape trauma when treated with risperidone.
- Trial name
- NCT00208182
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Creighton University
Bipolar Disorder
Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?
This study will evaluate the relative effectiveness of risperidone Consta injections occurring every 2 weeks in contrast to treatment as usual in preventing symptomatic relapse and rates of rehospitalization or admission into…
- Trial name
- Consta (NCT00571688)
- Testing
- Risperdal (risperidone) Consta, Treatment as usual
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Healthy Volunteer
A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers
This single-center, randomized, double-blind, two-period crossover study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of the combination of multiple doses of RO5285119 with a single dose of…
- Trial name
- NCT01708616
- Testing
- RO5285119, risperidone
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Depression
Quetiapine Extended Release Depression Symptoms
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
- Trial name
- ExAttitude (NCT00640562)
- Testing
- Quetiapine Extended Release, Risperidone
- Where
- 21 sites in Italy
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Child Development Disorders, Pervasive
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
The purpose of this research is to study the pharmacokinetics of risperidone in a group of pediatric patients with Pervasive Developmental Disorder (PDD).
- Trial name
- NCT00147394
- Testing
- Risperidone
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Schizophrenia
A Comparison of Seroquel vs. Risperidone in Schizophrenia
The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.
- Trial name
- NCT00034905
- Testing
- quetiapine fumarate vs risperidone
- Where
- 64 sites in United States
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Schizoaffective Disorder
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
- Trial name
- NCT00283179
- Testing
- Aripiprazole, Risperidone
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Schizophrenia, Extrapyramidal Syndrome
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00331825
- Testing
- Risperidone and Olanzapine
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Alzheimer's Disease, Dementia
Specific Interventions for Agitation in Alzheimer's Disease
This study is aimed at investigating specific pharmacological interventions in the treatment of the disruptive, agitated behavior associated with Alzheimer's patients.
- Trial name
- NCT00018291
- Testing
- Risperidone, Gabapentin
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa